San Diego, CA--Radicle Science, an AI-driven health tech B-corp pioneering large-scale clinical trials on health and wellness products, announced in a press release the results of history's largest cannabinoid clinical trial on pain, in partnership with Open Book Extracts (OBX), an NSF-certified manufacturer and distributor of cannabinoid ingredients and finished products.
[Image source: Radicle Science]
The OBX Pain Study on CBD and Rare Cannabinoids is the largest ever randomized, controlled clinical trial of cannabinoids for pain, involving more than 1600 participants from across the U.S. and the first of its kind to examine the synergistic impact of rare cannabinoids like Cannabichromene (CBC) and Cannabigerol (CBG) on pain.
Results demonstrated clinically meaningful improvements in pain across the different formulations of CBD and rare cannabinoids studied.